Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Vijan

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Effective Clinical Practice : ECP|February 24, 2001
Are we overvaluing performance measures?S Vijan
The Journal of Laboratory and Clinical Medicine|November 21, 1998
Normative issues in cost effectiveness analysisS D Goold, S Vijan
Microsurgery|August 21, 2007
Microvascular breast reconstruction pedicle thrombosis: how long can we wait?Sandeep S Vijan, V Nho Tran
American Journal of Obstetrics and Gynecology|December 1, 1990
The effect of maternal hyperoxia on behavioral activity in growth-retarded human fetusesR Gagnon, C Hunse, S Vijan
Annals of Internal Medicine|February 12, 1998
Estimated benefits of glycemic control in microvascular complications in type 2 diabetesS Vijan, T P Hofer, R A Hayward
JAMA|February 24, 2000
Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitusS Vijan, T P Hofer, R A Hayward
International Journal of Technology Assessment in Health Care|October 12, 2000
Estimating the microvascular benefits of screening for type 2 diabetes mellitusT P Hofer, S Vijan, R A Hayward
Diabetologia|February 15, 2000
Are randomized controlled trials sufficient evidence to guide clinical practice in type II (non-insulin-dependent) diabetes mellitus?S Vijan, D M Kent, R A Hayward
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 6, 2008
A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteriaM L Volk, S Vijan, J A Marrero
Annals of Internal Medicine|March 10, 2001
The cost-utility of screening for depression in primary careM Valenstein, S Vijan, J E Zeber, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Effective Clinical Practice : ECP|February 24, 2001
Are we overvaluing performance measures?S Vijan
The Journal of Laboratory and Clinical Medicine|November 21, 1998
Normative issues in cost effectiveness analysisS D Goold, S Vijan
Microsurgery|August 21, 2007
Microvascular breast reconstruction pedicle thrombosis: how long can we wait?Sandeep S Vijan, V Nho Tran
American Journal of Obstetrics and Gynecology|December 1, 1990
The effect of maternal hyperoxia on behavioral activity in growth-retarded human fetusesR Gagnon, C Hunse, S Vijan
Annals of Internal Medicine|February 12, 1998
Estimated benefits of glycemic control in microvascular complications in type 2 diabetesS Vijan, T P Hofer, R A Hayward
JAMA|February 24, 2000
Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitusS Vijan, T P Hofer, R A Hayward
International Journal of Technology Assessment in Health Care|October 12, 2000
Estimating the microvascular benefits of screening for type 2 diabetes mellitusT P Hofer, S Vijan, R A Hayward
Diabetologia|February 15, 2000
Are randomized controlled trials sufficient evidence to guide clinical practice in type II (non-insulin-dependent) diabetes mellitus?S Vijan, D M Kent, R A Hayward
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|March 6, 2008
A novel model measuring the harm of transplanting hepatocellular carcinoma exceeding Milan criteriaM L Volk, S Vijan, J A Marrero
Annals of Internal Medicine|March 10, 2001
The cost-utility of screening for depression in primary careM Valenstein, S Vijan, J E Zeber, et al.
Pageof 3